Registration number: 12253910

Bright Biotech Limited

Contents

Balance Sheet	1
Notes to the Unaudited Financial Statements	2 to 4

Bright Biotech Limited

(Registration number: 12253910)
Balance Sheet as at 31 December 2025

	Note	2025 £	2024 £
Fixed assets
Tangible assets	4	182,696	221,199
Current assets
Debtors	5	9,574	14,274
Cash at bank and in hand		442,124	667,115
		451,698	681,389
Creditors: Amounts falling due within one year	6	(21,778)	(21,437)
Net current assets		429,920	659,952
Net assets		612,616	881,151
Capital and reserves
Called up share capital		1	1
Share premium reserve		2,653,377	2,249,325
Retained earnings		(2,040,762)	(1,368,175)
Shareholders' funds		612,616	881,151

For the financial year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

Approved and authorised by the Board on 23 July 2026 and signed on its behalf by:
 

......................................... Dr Mohammad El Hajj Director

Bright Biotech Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

1	General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Rutherford House Unit 16 Pencroft Way
Manchester Science Park
Manchester
M15 6SZ
England

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Judgements

In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where revision affects only that period, or in the period of revision and future periods where the revision affects both current and future periods.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Bright Biotech Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Fixtures & fittings	15% Reducing balance
Computer equipment	20% Reducing balance
Plant & machinery	20% Reducing balance

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3	Staff numbers

The average number of persons employed by the company (including directors) during the year, was 10 (2024 - 8).

Bright Biotech Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

4	Tangible assets

	Fixtures and fittings £	Computer equipment £	Plant & machinery £	Total £
Cost or valuation
At 1 January 2025	42,801	6,186	311,278	360,265
Additions	-	-	4,029	4,029
At 31 December 2025	42,801	6,186	315,307	364,294
Depreciation
At 1 January 2025	13,187	1,535	124,344	139,066
Charge for the year	4,442	636	37,454	42,532
At 31 December 2025	17,629	2,171	161,798	181,598
Carrying amount
At 31 December 2025	25,172	4,015	153,509	182,696
At 31 December 2024	29,614	4,651	186,934	221,199

5

Debtors

Current	2025 £	2024 £
Prepayments	1,762	1,352
Other debtors	7,812	12,922
	9,574	14,274

6

Creditors

Creditors: amounts falling due within one year

	2025 £	2024 £
Due within one year
Trade creditors	6,353	6,261
Taxation and social security	10,120	10,910
Accruals and deferred income	3,359	1,450
Other creditors	1,946	2,816
	21,778	21,437